Brief: Sunshine Lake Pharma Says Insulin Degludec Injection, Others Obtain Marketing Approval
08/10/2026 13:09
BRIEF-Sunshine Lake Pharma Says Insulin Degludec Injection, Others Obtain Marketing Approval Oct 8 (Reuters) - Sunshine Lake Pharma Co Ltd 6887.HK:
INSULIN DEGLUDEC AND INSULIN ASPART INJECTION OBTAIN MARKETING APPROVAL FROM CHINA NMPA
Further company coverage: 6887.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sunshine Lake Pharma
See all newsBrief: Sunshine Lake Pharma Says Insulin Degludec Injection, Others Obtain Marketing Approval
Brief: Sunshine Lake Pharma Expects HY Loss Attributable RMB590 Million
Brief: Sunshine Lake Pharma Says Zhang Yushuai Purchases 1.5 Million H Shares
Brief: Sunshine Lake Pharma Obtains Nmpa Approval For Insulin Degludec Injection
Brief: Sunshine Lake Pharma Says Controlling Shareholder To Increase Shareholding By Hk$300 Million-Hk$600 Million In Next Six Months